Related Experiment Videos
Dextrans--potential polymeric drug carriers for suprofen.
S K Shrivastava1, D K Jain, P Trivedi
1College of Pharmacy, IPS Academy, Indore, India.
Die Pharmazie
|December 11, 2003
Summary
New suprofen-dextran conjugates were synthesized and show comparable anti-inflammatory activity to suprofen. These novel drug conjugates demonstrate significantly reduced ulcerogenic effects, offering a safer therapeutic option.
Area of Science:
- Polymer Chemistry
- Medicinal Chemistry
- Pharmacology
Background:
- Dextrans are biodegradable polysaccharides with clinical applications.
- Suprofen is a non-steroidal anti-inflammatory drug (NSAID).
- Drug conjugation aims to improve therapeutic profiles and reduce side effects.
Purpose of the Study:
- To synthesize and characterize suprofen-dextran conjugates.
- To evaluate the anti-inflammatory activity and ulcerogenic potential of these conjugates.
- To investigate the hydrolysis kinetics of the conjugates.
Main Methods:
- Suprofen was conjugated to dextrans of varying molecular weights (40-200 kDa) via acylimidazol derivatives.
- Conjugate structures were confirmed using IR and NMR spectroscopy.
- Hydrolysis, molecular weight, and biological activities (anti-inflammatory, ulcerogenic) were assessed.
Main Results:
- Suprofen-dextran conjugates were successfully synthesized with degrees of substitution between 7.5-9.0%.
- Hydrolysis followed first-order kinetics, with faster rates at pH 9.0.
- Conjugates exhibited comparable anti-inflammatory efficacy to suprofen but with a significantly reduced ulcerogenic index.
Conclusions:
- Suprofen-dextran conjugates represent a promising approach to developing safer NSAIDs.
- Dextran conjugation effectively mitigates the gastrointestinal toxicity associated with suprofen.
- These findings support the potential clinical utility of suprofen-dextran conjugates.